Glaukos, Epioxa, Epioxa HD, Keratoconus, Phase 3 Study, Clinical Trial Results, Corneal Cross-Linking, Ophthalmology, Corneal Disorders, Visual Acuity, Kmax,

ALISO VIEJO, Calif. — October 7, 2026 Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, announced...